Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGI-7079
- Development stage
- Preclinical
- Lead developer
- Sumitomo Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SGI-7079 is a small molecule inhibitor of the Axl receptor tyrosine kinase, a member of the TAM (Tyro3, Axl, Mer) family. Originally developed by SuperGen (now Astex Pharmaceuticals) for the treatment of solid tumors and hematological malignancies, SGI-7079 has more recently been investigated for its anti-inflammatory properties. Specifically, research conducted by institutions such as Suining Central Hospital has focused on its ability to inhibit the NLRP3 inflammasome-related inflammatory response. In models of gout, SGI-7079 has demonstrated the potential to reduce the production of interleukin-1 beta (IL-1β) and other inflammatory mediators triggered by monosodium urate (MSU) crystals. By blocking Axl-mediated signaling, the compound attenuates the activation of the NLRP3 complex, suggesting a potential therapeutic role in managing gouty arthritis flares.
02
Targets
AXL (AXL receptor tyrosine kinase)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)JAK2 (Janus kinase 2)MET (Mesenchymal-epithelial transition factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)SYK (Spleen Tyrosine Kinase)TYRO3 (TYRO3 protein tyrosine kinase)NTRK1 (Tropomyosin-related receptor kinase A)NTRK2 (Tropomyosin-related kinase receptor type B)VEGFR2 (Vascular endothelial growth factor receptor 2)YES1 (Tyrosine-protein kinase Yes)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on SGI-7079.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGI-7079.